A new clutch of biotech blue-chippers joins Obsidian's quest to craft next-gen drugs with an 'on' switch
The brainchild of serial biotech entrepreneur Michael Gilman, Obsidian is hoping to bring something new to the party with “on-switch” technology for a range of potential drug applications. Obsidian now has a new treasure chest to play with — and an IPO feels only a fingertip away.
Obsidian closed a $115 million Series B with a new group of biotech blue-blood investors joining the Cambridge, MA biotech’s already stacked syndicate of backers, the company said Thursday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.